<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药知说 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-06T17:32:18+08:00</updated>
  <subtitle>生物医药知识产权信息发布，包括医药专利，医药商标，医药网络域名等；生物医药知识产权数据分析，包括医药专利分析，医药商标与域名的冲突与分析，疾病治疗领域专利分析；生物医药知识产权信息检索，包括专利检索，商标检索，以及网络知识</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>泊马度胺Pomalyst(Pomalidomide)的又一件专利在日本获得保护期延长</title>
    <updated>2020-08-31T16:39:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-31:/s/OLGCsDMaYU_rRAR_jddRwg</id>
    <link href="https://mp.weixin.qq.com/s/OLGCsDMaYU_rRAR_jddRwg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>布美兰肽 Bremelanotide（Vyleesi）被公示专利保护期延长</title>
    <updated>2020-08-27T11:08:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-27:/s/PXXQyPVo4axI32SDPusggA</id>
    <link href="https://mp.weixin.qq.com/s/PXXQyPVo4axI32SDPusggA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>吡仑帕奈（卫克泰）Perampanel(Fycompa)在韩国获准专利保护期延长</title>
    <updated>2020-08-26T07:18:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-26:/s/GV6fBcxJxnPbnMBSphXOyw</id>
    <link href="https://mp.weixin.qq.com/s/GV6fBcxJxnPbnMBSphXOyw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>诺华的布洛赛珠单抗Beovu®(Brolucizumab)的登记专利在加拿大获专利保护期延长</title>
    <updated>2020-08-16T10:46:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-16:/s/rlZnnSzFYDf92OBATitR4g</id>
    <link href="https://mp.weixin.qq.com/s/rlZnnSzFYDf92OBATitR4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>泊马度胺Pomalyst(Pomalidomide)的专利在日本获得保护期延长</title>
    <updated>2020-08-15T12:06:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-15:/s/0tDm39iOTTAjSDBdfPuHqw</id>
    <link href="https://mp.weixin.qq.com/s/0tDm39iOTTAjSDBdfPuHqw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>巴洛沙韦玛波西酯在韩国获准专利保护期延长</title>
    <updated>2020-07-31T16:38:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-07-31:/s/4phQUh-WTPd1rOgHFqrM3w</id>
    <link href="https://mp.weixin.qq.com/s/4phQUh-WTPd1rOgHFqrM3w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>拜耳的达洛鲁胺Nubeqa®(darolutamide)的登记专利在加拿大获专利保护期延长</title>
    <updated>2020-07-29T09:32:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-07-29:/s/asxkmCtIgqPk-XnfHOo5FQ</id>
    <link href="https://mp.weixin.qq.com/s/asxkmCtIgqPk-XnfHOo5FQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>罗莫佐单抗Evenity(romosozumab)105mg注射液的专利在日本获得保护期延长</title>
    <updated>2020-07-20T20:36:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-07-20:/s/Im9BZOOcmcLX1qSRFM1tag</id>
    <link href="https://mp.weixin.qq.com/s/Im9BZOOcmcLX1qSRFM1tag" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年6月份美国FDA 临时批准了两款提出Piv挑战的首仿药</title>
    <updated>2020-07-16T09:19:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-07-16:/s/r04JYNok0NEfnzhUuiIwNQ</id>
    <link href="https://mp.weixin.qq.com/s/r04JYNok0NEfnzhUuiIwNQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>疫期药品专利在线公益系列讲座</title>
    <updated>2020-02-22T18:22:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-02-22:/s/8o4CKZBX8awQGN3mPvFbww</id>
    <link href="https://mp.weixin.qq.com/s/8o4CKZBX8awQGN3mPvFbww" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>